Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева
Список исп. литературыСкрыть список 1. Беккер Р.А., Быков Ю.В. Акатизия: клинический анализ патологии с рекомендациями и обзором литературы. http://www.con-med.ru/partner_article. / Bekker R.A., Bykov Yu.V. Akathisia: a clinical overview with literature review and recommendations. http://www.con-med.ru/partner_article. [in Russian] 2. Беккер Р.А., Быков Ю.В. Алимемазин: обзор применения. Психиатрия и психофармакотерапия. 2016; 18 (6): 10–20. / Bekker R.A., Bykov Yu.V. Alimemazine: a review. Psychiatry and Psychopharmacotherapy. 2016; 18 (6): 10–20. [in Russian] 3. Беккер Р.А., Быков Ю.В. Эффективность амисульприда в терапии депрессивных нарушений при шизофрении и других эндогенных психозах. Психиатрия и психофармакотерапия. 2016; 18 (3):19–26. / Bekker R.A., Bykov Yu.V. Amisulpride: effectiveness in relieving depressive symptoms in schizophrenia and other psychotic disorders. Psychiatry and Psychopharmacotherapy. 2016; 18 (3): 19–26. [in Russian] 4. Бобров А.Е., Мутных Е.М., Краснослободцева Л.А. Психопатологические и когнитивные нарушения при терапии шизоаффективного расстройства арипипразолом. Доктор.Ру. 2013; 5 (83): 81–5. / Bobrov A.E., Mutnykh E.M., Krasnoslobodtseva L.A. Psikhopatologicheskie i kognitivnye narusheniia pri terapii shizoaffektivnogo rasstroistva aripiprazolom. Doktor.Ru. 2013; 5 (83): 81–5. [in Russian] 5. Быков Ю.В., Беккер Р.А., Резников М.К. Депрессии и резистентность. Практическое руководство. М.: ИНФРА-М, 2013. / Bykov Iu.V., Bekker R.A., Reznikov M.K. Depressii i rezistentnost'. Prakticheskoe rukovodstvo. M.: INFRA-M, 2013. [in Russian] 6. Быков Ю.В., Беккер Р.А., Сюняков Т.С. Зипрасидон: баланс между эффектами, эффективностью и переносимостью. Психиатрия и психофармакотерапия. 2016; 18 (4): 52–62. / Bykov Yu.V., Bekker R.A., Syunyakov T.S. Ziprasidone: the past, the present and the future of an antipsychotic. Psychiatry and Psychopharmacotherapy. 2016; 18 (4): 52–62. [in Russian] 7. Быков Ю.В., Беккер Р.А. Сульпирид в терапии тревожных расстройств и тревожной симптоматики в рамках иных расстройств (обзор литературы). Психиатрия и психофармакотерапия. 2016; 18 (5): 29–37. / Bykov Yu.V., Bekker R.A. Effectiveness of an atypical antipsychotic sulpiride in the therapy of various anxiety disorders and anxiety symptoms present in other disorders (a review of the literature). Psychiatry and Psychopharmacotherapy. 2016; 18 (5): 29–37. [in Russian] 8. Быков Ю.В., Беккер Р.А. Хлорпротиксен: обзор применения в психиатрии (I часть). Психиатрия и психофармакотерапия. 2016; 18 (2): 26–32. / Bykov Yu.V., Bekker R.A. Chlorprothixene: a systematic review of its practical use in psychiatry (I part). Psychiatry and Psychopharmacotherapy. 2016; 18 (2): 26–32. [in Russian] 9. Горобец Л.Н. Вопросы переносимости и безопасности терапии арипипразолом (эндокринологический аспект проблемы). Соврем. терапия псих. расстройств. 2013; 1: 24–9. / Gorobets L.N. Voprosy perenosimosti i bezopasnosti terapii aripiprazolom (endokrinologicheskii aspekt problemy). Sovrem. terapiia psikh. rasstroistv. 2013; 1: 24–9. [in Russian] 10. Данилов Д.С., Магомедова Д.О. Опыт перевода с клозапина на арипипразол больных приступообразными формами шизофрении в период лекарственной ремиссии. Психиатрия и психофармакотерапия. 2013; 15 (6): 23–9. / Danilov D.S., Magomedova D.O. Transition experience from clozapine to aripiprazole with patients having intermittent schizophrenia within the period of therapeutic remission. Psychiatry and Psychopharmacotherapy. 2013; 15 (6): 23–9. [in Russian] 11. Дороженок И.Ю. Опыт применения атипичного антипсихотика арипипразола (Амдоала) в психиатрической практике. Соврем. терапия псих. расстройств. 2013; 4: 25–9. / Dorozhenok I.Iu. Opyt primeneniia atipichnogo antipsikhotika aripiprazola (Amdoala) v psikhiatricheskoi praktike. Sovrem. terapiia psikh. rasstroistv. 2013; 4: 25–9. [in Russian] 12. Иванов М.В., Шипилин М.Ю., Банщиков Ф.Р. Опыт применения арипипразола (Абилифая) в лечении больных шизофренией. Соц. и клин. психиатрия. 2009; 19 (2): 46–50. / Ivanov M.V., Shipilin M.Iu., Banshchikov F.R. Opyt primeneniia aripiprazola (Abilifaia) v lechenii bol'nykh shizofreniei. Sots. i klin. psikhiatriia. 2009; 19 (2): 46–50. [in Russian] 13. Костюкова Е.Г. Арипипразол как средство аугментации при неэффективности терапии антидепрессантами у больных с большим депрессивным расстройством. Соц. и клин. психиатрия. 2010; 20 (3): 100–5. / Kostiukova E.G. Aripiprazol kak sredstvo augmentatsii pri neeffektivnosti terapii antidepressantami u bol'nykh s bol'shim depressivnym rasstroistvom. Sots. i klin. psikhiatriia. 2010; 20 (3): 100–5. [in Russian] 14. Любов Е.Б. Арипипразол (Абилифай): рациональный выбор при лечении шизофрении. Соц. и клин. психиатрия. 2008; 18 (4): 94–102. / Liubov E.B. Aripiprazol (Abilifai): ratsional'nyi vybor pri lechenii shizofrenii. Sots. i klin. psikhiatriia. 2008; 18 (4): 94–102. [in Russian] 15. Морозов П.В. Арипипразол (Абилифай) – новый атипичный антипсихотик. Психиатрия и психофармакотерапия. 2006; 8 (4): 14–7. / Morozov P.V. Aripiprazol (Abilifai) – novyi atipichnyi antipsikhotik. Psychiatry and Psychopharmacotherapy. 2006; 8 (4): 14–7. [in Russian] 16. Нуллер Ю.Л., Михаленко И.Н. Аффективные психозы. Л.: Медицина, 1988. / Nuller Iu.L., Mikhalenko I.N. Affektivnye psikhozy. L.: Meditsina, 1988. [in Russian] 17. Оруджев Н.Я., Можаров Н.С. Арипипразол (Амдоал): атипичный нейролептик при лечении шизофрении. Лекарств. вестнк. 2014; 2 (54): 30–2. / Orudzhev N.Ia., Mozharov N.S. Aripiprazol (Amdoal): atipichnyi neiroleptik pri lechenii shizofrenii. Lekarstv. vestnk. 2014; 2 (54): 30–2. [in Russian] 18. Поткин С.Г., Саха А.Р., Куява М.Дж. и др. Арипипразол, атипичный антипсихотик с новым механизмом действия и рисперидон в сравнении с плацебо у больных шизофренией и шизоаффективным расстройством. Соц. и клин. психиатрия. 2007; 17 (2): 72–9. / Potkin S.G., Sakha A.R., Kuiava M.Dzh. i dr. Aripiprazol, atipichnyi antipsikhotik s novym mekhanizmom deistviia i risperidon v sravnenii s platsebo u bol'nykh shizofreniei i shizoaffektivnym rasstroistvom. Sots. i klin. psikhiatriia. 2007; 17 (2): 72–9. [in Russian] 19. Тарасевич Л.А., Колесникова А.В. Влияние терапии арипипразолом на негативную симптоматику больных шизофренией, совершивших общественно опасные действия. Соц. и клин. психиатрия. 2010; 20 (2): 45–7. / Tarasevich L.A., Kolesnikova A.V. Vliianie terapii aripiprazolom na negativnuiu simptomatiku bol'nykh shizofreniei, sovershivshikh obshchestvenno opasnye deistviia. Sots. i klin. psikhiatriia. 2010; 20 (2): 45–7. [in Russian] 20. Шафаренко А.А., Капилетти С.Г. Эффективность и переносимость арипипразола при купировании маниакальных состояний. Соц. и клин. психиатрия. 2009; 19 (1): 102–7. / Shafarenko A.A., Kapiletti S.G. Effektivnost' i perenosimost' aripiprazola pri kupirovanii maniakal'nykh sostoianii. Sots. i klin. psikhiatriia. 2009; 19 (1): 102–7. [in Russian] 21. Шмуклер А.Б. Арипипразол: обзор применения в натуралистических условиях. Соц. и клин. психиатрия. 2008; 18 (2): 103–6. / Shmukler A.B. Aripiprazol: obzor primeneniia v naturalisticheskikh usloviiakh. Sots. i klin. psikhiatriia. 2008; 18 (2): 103–6. [in Russian] 22. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005; 86: 99–104. 23. Adam RL, Sidi H, Midin M et al. The role of atypical antipsychotics in sexuality: Road to recovery in schizophrenia. Curr Drug Targets 2017. 24. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22–31. 25. Ammar G, Naja WJ, Pelissolo A. Treatment-resistant anxiety disorders: A literature review of drug therapy strategies. [Article in French]. Encephale 2015; 41 (3): 260–5. 26. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004; 24: 212–8. 27. Arikawa A, Mito H, Motoyama M et al. A Case with Multiple Comorbidities of Obsessive-Compulsive and Related Disorders. [Article in Japanese]. Seish Shinkeig Zasshi 2015; 117 (11): 893–901. 28. Barber S, Olotu U, Corsi M et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev 2017; 3: CD006324. 29. Bellino S, Rinaldi C, Bozzatello P et al. Pharmacotherapy of borderline personality disorder: a systematic review for publication purpose. Curr Med Chem 2011; 18 (22): 3322–9. 30. Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197–206. 31. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843–53. 32. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008; CD006617. 33. Blonde L, Kan HJ, Gutterman EM et al. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. J Clin Psychiatry 2008; 69 (5): 741–8. 34. Buckley P.F., Sebastian S. Арипипразол: оценка влияния комплексного рецепторного воздействия на клинические исходы. Психиатрия и психофармакотерапия. 2007; 9 (4): 58–63. / Buckley P.F., Sebastian S. Aripiprazol: otsenka vliianiia kompleksnogo retseptornogo vozdeistviia na klinicheskie iskhody. Psychiatry and Psychopharmacotherapy. 2007; 9 (4): 58–63. [in Russian] 35. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302 (1): 381–9. 36. CADTH Rapid Response Reports.Aripiprazole for Borderline Personality Disorder: A Review of the Clinical Effectiveness. Canadian Agency for Drugs and Technologies in Health. 2017. 37. Carbray MJ, McGuinness T. Pediatric bipolar disorder. J Psychosoc Nurs Ment Health Serv 2009; 47 (12): 22–6. 38. Carson WH et al. Aripiprazole vs. placebo in the treatment of chronic schizophrenia. Int J Neurops 2002; 5: 186–8. 39. Carson WH, Pigott TA, Saha AR et al. Aripiprazole vs. placebo in the treatment of chronic schizophrenia. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1): S187. 40. Carter WG, Shillcutt SD. Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation. J Clin Psychiatry 2006; 67 (8): 1311. 41. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. Case Rep Med 2010; 2010: 836214. 42. Celik G, Tahiroglu AY, Firat S, Avci A. Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder. Clin Psychopharmacol Neurosci 2011; 9 (3): 134–6. 43. Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004; 19: 351–3. 44. Chan HY, Lin WW, Lin SK et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007; 29–36. 45. Choi-Kain LW, Gunderson JG. Borderline Personality and Mood Disorders: Comorbidity and Controversy. NY: Springer, 2014; ISBN 978-1493913138. 46. Christensen WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacol 2006; 113: 148–53. 47. Chrzanowski WK, Marcus RN, Torbeyns A et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacol 2006; 189 (2): 259–66. 48. Cohen J, Magalon D, Boyer L et al. Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf 2011; 6 (1): 51–3. 49. Curtis AR, Richards RW. The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine. Ann Clin Psychiatry 2007; 19 (3): 199–200. 50. Daniel DG, Saha AR, Inenito G et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result. Int J Neuropsyhopharmacol 2000; 3 (Suppl. 1): S157. 51. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10 (4): 317–36. 52. De Bartolomeis A, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs 2015; 29 (9): 773–99. 53. De Hert M, Hanssens L, van Winkel R et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33: 823–30. 54. DeFilippis M, Wagner KD. Treatment of Autism Spectrum Disorder in Children and Adolescents. Psychopharmacol Bull 2016; 46 (2): 18–41. 55. Delle Chiaie R, Scarciglia P, Pasquini M et al. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin Pract Epidemiol Ment Health 2011; 7: 107–11. 56. Di Lorenzo R, Amoretti A, Forghieri M et al. Aripiprazole: effectiveness and safety under naturalistic conditions. Exp Clin Psychopharmacol 2007; 15 (6): 569–75. 57. Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat 2015; 11: 2635–47. 58. Dold M, Aigner M, Lanzenberger R et al. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. Int J Neuropsychopharmacol 2015; 18 (9). pii: pyv047. 59. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006; 2: CD004578. 60. Ercan ES, Uysal T, Ercan E et al. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study. Pharmacopsychiatry 2012; 45 (1): 13–9. 61. Farlow MR, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol 2017. pii: S0924-977X(17)30015-9. 62. Findling RL, Short EJ, Leskovec T et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18 (4): 347–54. 63. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008; 69 (Suppl. 4): 9–14. 64. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6: 2091–101. 65. Fornaro M, Gabrielli F, Mattei C et al. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann Gen Psychiatry 2008; 7: 26. 66. Frank GK. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series. Int J Eat Disord 2016; 49 (5): 529–33. 67. Frank GK, Shott ME, Hagman JO et al. The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa. Int J Eat Disord 2017; 50 (4): 447–50. 68. Freire RC, Zugliani MM, Garcia RF et al. Treatment-resistant panic disorder: a systematic review. Expert Opin Pharmacother 2016; 17 (2): 159–68. 69. Gaboriau L, Victorri-Vigneau C, Gérardin M et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav 2014; 39 (3): 562–5. 70. Gao K, Muzina D, Gajwani P et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67 (9): 1327–40. 71. Geoffroy PA, Rolland B, Guardia D et al. Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder. J Neuropsychiatry Clin Neurosci 2012; 24 (2): E37. 72. Gerasch S, Kanaan AS, Jakubovski E et al. Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. Front Neurosci 2016; 10: 416. 73. Ghanizadeh A. Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. Neurosciences (Riyadh) 2013; 18 (4): 323–9. 74. Glick ID, Poyurovsky M, Iranova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry 2008; 69: 1856–9. 75. Gross G. Therapy of subclinical (subdiagnostic) syndromes of schizophrenia spectrum. [Article in German]. Fortschr Neurol Psychiatr 2001; 69 (Suppl. 2): S95–100. 76. Gründer G, Kungel M, Ebrecht M et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl. 1): S21–5. 77. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 911–36. 78. Han C, Wang SM, Lee SJ et al. Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Med J 2015; 51 (2): 66–80. 79. Harada T, Yamada K, Sakamoto K et al. Aripiprazole augmentation for a patient with partial remission of panic disorder. J Clin Psychopharmacol 2009; 29 (3): 301–2. 80. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009; 206 (3): 345–54. 81. Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs 2014; 28 (6): 519–33. 82. Hirose T, Uwahodo Y, Yamada S et al. Mechanism of action of aripiprazole predicts clinical efficacy and favorable side-effect profile. J Psychopharmacol 2004; 18: 375–83. 83. Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2016; 6: CD009043. 84. Hoge EA, Worthington JJ, Kaufman RE et al. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008; 13 (6): 522–7. 85. Hollis C, Pennant M, Cuenca J et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess 2016; 20 (4): 1–450, vii–viii. 86. Huang SC, Tsai SJ, Yang HJ. Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder. Chang Gung Med J 2010; 33 (2): 211–5. 87. Ichikawa H, Mikami K, Okada T et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev 2016. 88. Jefferys D, Burrows G. Reversal of trichotillomania with aripiprazole. Depress Anxiety 2008; 25 (6): E37–40. 89. Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 137–40. 90. Jordan S, Koprivica V, Dunn R et al. In vitro effects of aripiprazole on cortical and striatal dopaminergic and serotoninergic function. Eur J Pharmacol 2004; 483: 45–53. 91. Kane JM, Carson WH, Saha AR et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63 (9): 763–71. 92. Kane JM, Meltzer HY, Carson WH et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007; 68: 213–23. 93. Kasper S, Lerman MN, McQuade RD et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325–37. 94. Keck P, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8. 95. Keck PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480–91. 96. Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626–37. 97. Kelly T, Lieberman DZ. The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression. J Clin Psychopharmacol 2017; 37 (1): 99–101. 98. Kemp DE, Gilmer WS, Fleck J et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31 (2): 574–7. 99. Kerwin R, L’Italien G, Hanssens L et al. Effectiveness of Aripiprazole Versus Standard of Care Treatment in Patients With Schizophrenia: The Schizophrenia Trial of Aripiprazole (STAR) Study. 19th European College of Neuropsychopharmacology (ECNP) Congress. Paris, France, September 16–20, 2006. 100. Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007; 22 (7): 433–43. 101. Koch M. Aripiprazole – the prototypical dopamine-serotonin system stabilizer for the pharmacotherapy of schizophrenia. Nervenheilkunde 2004; 3; 123–85. 102. Kołaczkowski M, Mierzejewski P, Bienkowski P et al. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol 2014; 387 (6): 545–57. 103. Kozian R. Brief case report. Duloxetine in Cotard syndrome. [Article in German]. Psychiatr Prax 2005; 32 (8): 412–3. 104. Kujava M, Saha AR, Ingenito GG et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002; 5 (Suppl. 1): S186. 105. Kumar A, Pinjarkar R, Anand N et al. Aripiprazole in schizotypal personality disorder: a case report. Prim Care Companion J Clin Psychiatry 2008; 10 (6): 481–2. 106. Lai CH. Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder. J Clin Psychopharmacol 2010; 30 (4): 474–6. 107. Lambert MT. Aripiprazole in the management of post-traumatic stress disorder symptoms in returning Global War on Terrorism veterans. Int Clin Psychopharmacol 2006; 21 (3): 185–7. 108. Lamberti M, Siracusano R, Italiano D et al. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Paediatr Drugs 2016; 18 (4): 319–29. 109. Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209–23. 110. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18: 251–67. 111. Liu Y, Ni H, Wang C et al. Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Meta-Analysis. J Child Adolesc Psychopharmacol 2016; 26 (5): 436–41. 112. Lublin H, Eberhard J, Levander S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol 2005; 20 (4): 183–98. 113. Madhusoodanan S, Brenner R, Gupta S et al. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS Spectr 2004; 9: 862–7. 114. Malempati RN. Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study. J Nerv Ment Dis 2015; 203 (1): 58–64. 115. Mamo D, Graff A, Mizrahi R et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007; 164: 1411–7. 116. Mancini-Marïe A, Fahim C, Potvin S et al. Quetiapine: focus on emotional numbing in depersonalization disorder: an fMRI case report. Eur Psychiatry 2006; 21 (8): 574–7. 117. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156–65. 118. Marder SR, McQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61 (2–3): 123–36. 119. Marder SR, West B, Lau GS et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007; 68: 662–8. 120. Marder SR. Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand 2005; 111: 43–6. 121. Marzola E, Desedime N, Giovannone C et al. Atypical antipsychotics as augmentation therapy in anorexia nervosa. PLoS One 2015; 10 (4): e0125569. 122. Masi G, Gagliano A, Siracusano R et al. Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol 2012; 22 (2): 120–5. 123. Mason O, Claridge G. Schizotypy: New dimensions (Advances in Mental Health Research). Routledge, 2015; ISBN 978-0415722032. 124. Mauri MC, Paletta S, Maffini M et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014; 13: 1163–91. 125. McQuade RD, Burris КD, Jordan S et al. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5 (1): 176. 126. Medori R., Gharbia N et al. Switching to aripiprazole monotherapy. Eur Neuropsychoparm 2002; 12: 292–3. 127. Meduri M, Gregoraci G, Baglivo V et al. A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies. J Affect Disord 2016; 191: 187–208. 128. Mello MF, Costa MC, Schoedl AF, Fiks JP. Aripiprazole in the treatment of posttraumatic stress disorder: an open-label trial. Rev Bras Psiquiatr 2008; 30 (4): 358–61. 129. Mété D, Dafreville C, Paitel V et al. Aripiprazole, gambling disorder and compulsive sexuality. [Article in French]. Encephale 2016; 42 (3): 281–3. 130. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus 2016; 8 (4): 562. 131. Muneer A. The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review. Cureus 2016; 8 (4): e562. 132. Murphy TK, Mutch PJ, Reid JM et al. Open label Aripiprazole in the treatment of youth with Tic Disorder. J Child and Adolescent Psychopharmacol 2009; 19: 441–7. 133. Naber D, Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Progress in Neuropsychoparmacology. J Biol Psychiatry 2004; 28: 1213–19. 134. Naglich A, Adinoff B, Brown ES. Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder. CNS Drugs 2017; 31 (8): 665–74. 135. Nakagawa M, Yamamura S, Motomura E et al. Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia. J Neuropsychiatry Clin Neurosci 2012; 24 (Summer 3): E9. 136. Naylor JC, Kilts JD, Bradford DW et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. Int Clin Psychopharmacol 2015; 30 (3): 167–74. 137. Newcomer J.W. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl. 1): 1–93. 138. Newcomer JW, Campos JA, Marcus RN et al. A multicenter, randomized, double blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69 (7): 1046–56. 139. Oh GH, Yu JC, Choi KS et al. Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsychotics in Schizophrenia: Mixed-Treatment Comparison Analysis Based on Head-to-Head Trial Data. Psychiatry Investig 2015; 12 (1): 46–54. 140. Padala PR, List D, Petty F, Bhatia SC. Adjunctive aripiprazole in combat-related posttraumatic stress disorder. Ann Pharmacother 2007; 41 (10): 1744. 141. Pae CU, Patkar AA, Jun TY et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007; 24: 522–6. 142. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326–30. 143. Patkar AA, Peindl K, Mago R et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006; 8: 82–7. 144. Petrie JL, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase II clinical trial result. Eur Neuropsychopharmacol 1997; 7 (Suppl. 2): S227. 145. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28 (3): 191–208. 146. Pigott TA, Carson WH, Saha AR et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–56. 147. Potkin SG, Saha AR, Kujawa MJ et al. Aripirazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60 (7): 681–90. 148. Prommer E. Aripiprazole. Am J Hosp Palliat Care 2017; 34 (2): 180–5. 149. Raine A, Lencz T, Mednick SA. Schizotypal Personality. 1st Ed. Cambridge University Press, 1995; ISBN 978-0521454223. 150. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71 (7): 839–54. 151. Ripoll LH. Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders – 5. Curr Opin Psychiatry 2012; 25 (1): 52–8. 152. Roxanas MG. Pathological gambling and compulsive eating associated with aripiprazole. Aust N Z J Psychiatry 2010; 44 (3): 291. 153. Sachs G, Sanchez R, Marcus R et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. Aripiprazole Study Group. J Psychopharmacol 2006; 20: 536–46. 154. Saddichha S, Kumar R, Babu GN et al. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. J Clin Pharmacol 2012; 52 (9): 1448–9. 155. Safavi P, Hasanpour-Dehkordi A, AmirAhmadi M. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial. J Adv Pharm Technol Res 2016; 7 (2): 43–7. 156. Salmoiraghi A, Odiyoor M. A case of Aripiprazole and extrapyramidal side effects. J Psychopharmacol 2006; 20: 592–3. 157. Samuel M, Zimovetz EA, Gabriel Z et al. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol 2011; 26 (2): 63–8. 158. Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 2008; 22: 335–52. 159. Sepede G, Di Iorio G, Spano MC et al. A Case of Resistant Schizophrenia Successfully Treated With Clozapine/Long-acting Injectable Aripiprazole Combination. Clin Neuropharmacol 2016; 39 (6): 322–4. 160. Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003; 4: 1400–11. 161. Shim JC, You YS, Kelly DL. Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report. J Clin Psychopharmacol 2008; 28: 353–4. 162. Shoja Shafti S, Kaviani H. Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. Ther Adv Psychopharmacol 2015; 5 (1): 32–7. 163. Sierra M. Depersonalization: A New Look at a Neglected Syndrome. 1st Ed. Cambridge University Press, 2009; ISBN 978-0521874984. 164. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216–20. 165. Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry 2011; 199 (2): 158–9. 166. Spielmans GI, Berman MI, Linardatos E et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10 (3): e1001403. 167. Srisurapanont M, Suttajit S, Maneeton N et al. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J Psychiatr Res 2015; 62: 38–47. 168. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841–2. 169. Stahl SM. Stahl's Essential Psychopharmacology. Neuroscientific Basis and Practical Application. 4th Ed. Cambridge University Press, 2013; ISBN 978-1107025981. 170. Stern RG, Petti TA, Bopp K et al. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol 2009; 29 (3): 206–9. 171. Stokes PRA, Kalk NJ, Young AH. Bipolar disorder and addictions: the elephant in the room. Br J Psychiatry 2017; 211 (3): 132–4. 172. Sullivan G, Bienroth M, Jones M et al. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 2007; 23: 1733–44. 173. Takaki M, Okabe N. Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders. J Clin Psychopharmacol 2015; 35 (1): 93–5. 174. Tandon R, Jibson M. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int J Psychiatry Clin Practice 2005; 9 (3): 204–12. 175. Tashiro T. Improvement of a patient's circadian rhythm sleep disorders by aripiprazole was associated with stabilization of his bipolar illness. J Sleep Res 2017. 176. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in non-psychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28 (1): 13–20. 177. Thome J, Kopf D. Haematological abnormalities during treatment with atypical antipsychotics. Psychiatr Prax 2005; 32 (4): 167–71. 178. Travis M, Burns T, Dursun S et al. Арипипразол при шизофрении: согласованное руководство (расширенный реферат). Психиатрия и психофармакотерапия. 2006; 8 (5): 79–87. / Travis M, Burns T, Dursun S et al. Aripiprazol pri shizofrenii: soglasovannoe rukovodstvo (rasshirennyi referat). Psychiatry and Psychopharmacotherapy. 2006; 8 (5): 79–87. [in Russian] 179. Tripathi P, Goyal P, Kumar D et al. High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. Aust N Z J Psychiatry 2015; 49 (2): 185. 180. Tsai AC, Rosenlicht NZ, Jureidini JN et al. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 2011; 8 (5): e1000434. 181. Turner GA, Sutton S, Sharma A. Augmentation of Venlafaxine with Aripiprazole in a Case of Treatment-resistant Excoriation Disorder. Innov Clin Neurosci 2014; 11 (1–2): 29–31. 182. Uguz F, Sahingoz M. Aripiprazole in depersonalization disorder comorbid with major depression and obsessive-compulsive disorder: 3 cases. Clin Neuropharmacol 2014; 37 (4): 125–7. 183. Uguz F. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry 2010; 32: 556–8. 184. Uzun O, Ozdemir B. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. Clin Drug Investig 2010; 30 (10): 707–10. 185. Veale D, Miles S, Smallcombe N et al. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 317. 186. Veerman SRT, Schulte PFJ, de Haan L. Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. Drugs 2017. 187. Vieta E, Bourin M, Sanchez R et al. Effectiveness of aripiprazole vs haloperidol in acute bipolar mania: double-blind, randomised comparative 12-week trial. Br J Psychiatry 2005; 187: 235–42. 188. Vieta E, T'joen C, McQuade RD et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008; 165: 1316–25. 189. Villarreal G, Calais LA, Cañive JM et al. Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial. Psychopharmacol Bull 2007; 40 (2): 6–18. 190. Virit O, Selek S, Savas HA et al. Improvement of restless legs syndrome and trichotillomania with aripiprazole. J Clin Pharm Ther 2009; 34 (6): 723–5. 191. Wang LJ, Chou WJ, Chou MC et al. The Effectiveness of Aripiprazole for Tics, Social Adjustment, and Parental Stress in Children and Adolescents with Tourette's Disorder. J Child Adolesc Psychopharmacol 2016; 26 (5): 442–8. 192. Wenzel C, Kleimann A, Bokemeyer S et al. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol 2012; 32 (4): 548–50. 193. White MP, Koran LM. Open-label trial of aripiprazole in the treatment of trichotillomania. J Clin Psychopharmacol 2011; 31 (4): 503–6. 194. Winans E. Aripiprazole. Am J Health Syst Pharm 2003; 60: 2437–45. 195. Wink LK, Erickson CA, McDougle CJ. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol 2010; 12 (6): 529–38. 196. Wolf J, Janssen F, Lublin H et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007; 23: 2313–23. 197. Woods SW, Tully EM, Walsh BC et al. Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 2007; 51: s96–101. 198. Worthington JJ, Kinrys G, Wygant LE et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20 (1): 9–11. 199. Yavuz KF, Ulusoy S, Alnıak İ. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 2013; 25 (2): E31. 200. Yokoi F, Grunder G, Biziere K et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and (11C) raclopride. Neuropsychopharmacology 2002; 27 (2): 248–59. 201. Zhu Y, Krause M, Huhn M et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017; 4 (9): 694–705.